FDA Clears Zabalafin Hydrogel IND for Atopic Dermatitis Treatment, Phase 2b Trials to Begin in 2025
Key Insights
Alphyn Biologics (search) receives FDA clearance for Investigational New Drug application of Zabalafin Hydrogel, a novel botanical drug targeting multiple pathways in atopic dermatitis (search).
Phase 2a trials demonstrated significant improvements in itch relief, quality of life, and skin inflammation, with minimal adverse events and high patient tolerability.
The company plans to initiate global phase 2b clinical trials in Q1 2025, advancing development of this first-in-class treatment for mild to moderate atopic dermatitis (search).
Alphyn Biologics (search) has achieved a significant regulatory milestone with the US Food and Drug Administration (FDA) clearing their Investigational New Drug (IND) application for Zabalafin Hydrogel, a novel topical treatment for mild to moderate atopic dermatitis (search) (AD).
The innovative therapy represents a potential breakthrough in AD treatment, utilizing a complex, single-source botanical drug formulation that contains multiple bioactive compounds. Unlike existing treatments that typically target individual aspects of AD, Zabalafin Hydrogel is designed to simultaneously address multiple pathophysiological factors, including pruritus, bacterial imbalance, and immunoinflammatory processes (search).
Promising Phase 2a Results
Early clinical evidence has demonstrated encouraging outcomes for the experimental treatment. In phase 2a trials, Zabalafin Hydrogel met both primary and secondary endpoints, showing clinically meaningful improvements across multiple measures. Patients experienced significant relief from itching, reduced skin inflammation, and improved quality-of-life scores. Notably, the treatment demonstrated an excellent safety profile with minimal adverse events and favorable patient tolerability.
Comprehensive Treatment Approach
Neal Koller, CEO of Alphyn, emphasized the significance of this development: "Zabalafin Hydrogel is on the cutting edge of an evolution in AD therapeutics to treat directly for the first time all aspects of the disease simultaneously. We believe it will be the compelling therapeutic choice to treat AD, offering excellent patient tolerability for worry free, long-term and continuous use."
The treatment's comprehensive approach is particularly relevant given the complex nature of atopic dermatitis (search), which affects patients with recurring symptoms of pruritus, inflammation, and compromised skin barrier function. The Zabalafin Platform, which forms the foundation of this therapy, incorporates a broad spectrum of mechanisms of action specifically designed for dermatologic applications.
Development Timeline
With the FDA clearance secured, Alphyn Biologics (search) is now positioned to advance their clinical development program. The company has announced plans to initiate global phase 2b clinical trials in the first quarter of 2025, marking the next crucial step in bringing this potential first-in-class treatment to market.